OSL is Moving, page-11

My uncle has worked in the pharma industry for over 30 years, specialising in oncology. He has spent the last 15 years or so holding various board roles on different pharma co's. I sent him a bunch of OSL materials last week and met up with yesterday to discuss. He told me that within the industry the OSL management team has a great reputation and that the oncosil product has been on everyone's radar and has a fair amount of hype and optimism. His experience with the IDE process is that it can be lengthy but purely due to redtape. He said a product like oncosil shouldn't face too much head wind because of the precedent set by similar products already i.e. SIR-Spheres. The nature of pancreatic cancer is that it just wipes you out before you have a chance you combat it, for this reason the market is extremely underserviced and with potential annual revenues of $10bn that oncosil could generate, OSL is a great position to capitalise on it.